AIM Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -10571.43% compared to AIM ImmunoTech's net margin of --. AIM ImmunoTech's return on equity of -256.33% beat Perspective Therapeutics's return on equity of --.

AIM ImmunoTech has a consensus price target of $2.75, signalling upside risk potential of 1167.28%. On the other hand Perspective Therapeutics has an analysts' consensus of $16.15 which suggests that it could grow by 357.51%. Given that AIM ImmunoTech has higher upside potential than Perspective Therapeutics, analysts believe AIM ImmunoTech is more attractive than Perspective Therapeutics.

AIM ImmunoTech has a beta of -0.363, which suggesting that the stock is 136.26% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.195, suggesting its more volatile than the S&P 500 by 19.546%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are $35K, which are larger than Perspective Therapeutics quarterly revenues of --. AIM ImmunoTech's net income of -$3.7M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 59.64x versus 19.06x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Electromed has a net margin of -10571.43% compared to AIM ImmunoTech's net margin of 10.05%. AIM ImmunoTech's return on equity of -256.33% beat Electromed's return on equity of 15.62%.

AIM ImmunoTech has a consensus price target of $2.75, signalling upside risk potential of 1167.28%. On the other hand Electromed has an analysts' consensus of -- which suggests that it could grow by 6.04%. Given that AIM ImmunoTech has higher upside potential than Electromed, analysts believe AIM ImmunoTech is more attractive than Electromed.

AIM ImmunoTech has a beta of -0.363, which suggesting that the stock is 136.26% less volatile than S&P 500. In comparison Electromed has a beta of 0.314, suggesting its less volatile than the S&P 500 by 68.592%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are $35K, which are smaller than Electromed quarterly revenues of $14.7M. AIM ImmunoTech's net income of -$3.7M is lower than Electromed's net income of $1.5M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Electromed's PE ratio is 43.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 59.64x versus 4.86x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Protalix BioTherapeutics has a net margin of -10571.43% compared to AIM ImmunoTech's net margin of 18.02%. AIM ImmunoTech's return on equity of -256.33% beat Protalix BioTherapeutics's return on equity of -29.54%.

AIM ImmunoTech has a consensus price target of $2.75, signalling upside risk potential of 1167.28%. On the other hand Protalix BioTherapeutics has an analysts' consensus of -- which suggests that it could grow by 516.74%. Given that AIM ImmunoTech has higher upside potential than Protalix BioTherapeutics, analysts believe AIM ImmunoTech is more attractive than Protalix BioTherapeutics.

AIM ImmunoTech has a beta of -0.363, which suggesting that the stock is 136.26% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.711, suggesting its less volatile than the S&P 500 by 28.881%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are $35K, which are smaller than Protalix BioTherapeutics quarterly revenues of $18M. AIM ImmunoTech's net income of -$3.7M is lower than Protalix BioTherapeutics's net income of $3.2M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 121.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 59.64x versus 3.90x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -10571.43% compared to AIM ImmunoTech's net margin of -17.98%. AIM ImmunoTech's return on equity of -256.33% beat Xtant Medical Holdings's return on equity of -35.98%.

AIM ImmunoTech has a consensus price target of $2.75, signalling upside risk potential of 1167.28%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 381.39%. Given that AIM ImmunoTech has higher upside potential than Xtant Medical Holdings, analysts believe AIM ImmunoTech is more attractive than Xtant Medical Holdings.

AIM ImmunoTech has a beta of -0.363, which suggesting that the stock is 136.26% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.343, suggesting its less volatile than the S&P 500 by 65.673%.

AIM ImmunoTech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AIM ImmunoTech pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

AIM ImmunoTech quarterly revenues are $35K, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. AIM ImmunoTech's net income of -$3.7M is higher than Xtant Medical Holdings's net income of -$5M. Notably, AIM ImmunoTech's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AIM ImmunoTech is 59.64x versus 0.55x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.